Serum GGT activity and hsCRP level in patients with type 2 diabetes mellitus with good and poor glycemic control: An evidence linking oxidative stress, inflammation and glycemic control

Journal of Diabetes and Metabolic Disorders

Volumn 12, Issue 1, 2013, Pages

  Gohel, Mukesh G ^a   Chacko, Anusha N ^b  

^a CIVIL HOSPITAL   (India)

^b Department of Biochemistry GDERS Dental College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CALCINEURIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84904511077     PISSN: None     EISSN: 22516581     Source Type: Journal    
DOI: 10.1186/2251-6581-12-56     Document Type: Article

References (39)

1. Alvin C. Powers: diabetes mellitus. Harrison's Principle of Internal Medicine 2005, 2152-2179. New York: McGraw-Hill, et al, Kasper L, 16.
2. Thakur S, Chauhan V, Negi RC. Role of HbA1C in diabetes mellitus. J Indian Acad Clin Med 2009, 10(1&2):52-54.
3. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen and leucocyte count: findings from the third national health and nutrition examination survey. Atherosclerosis 2003, 168:351-358. 10.1016/S0021-9150(03)00134-5, 12801619.
4. Emdin M, Pompella A, Paolicchi A. Gammaglutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080. 10.1161/CIRCULATIONAHA.105.571919, 16203922.
5. Karp DR, Shimooku K, Lipsky PE. Expression of gamma-glutamyl transpeptidase protects ramos B cells from oxidation-induced cell death. J Biol Chem 2001, 276:3798-3804. 10.1074/jbc.M008484200, 11080500.
6. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002, 82:47-95.
7. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American diabetes association and the German diabetes society. Diabetes Metabolic Research Rev 2001, 17:189-212.
8. Marchesini G, Brizi M, Bianchi G. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-50. 10.2337/diabetes.50.8.1844, 11473047.
9. Lee DH, Ha MH, Kim JH. Gamma-glutamyltransferase and diabetes: a 4 year follow-up study. Diabetologia 2003, 46:359-364.
10. Pfützner A, Forst T. High-sensitivity C-reactive protein as cardio-vascular risk marker in patients with diabetes mellitus. Diabetes Technol Ther 2006, 8(1):28-36. 10.1089/dia.2006.8.28, 16472048.
11. Amanullah S, Jarari A, Govindan M. Mohamed Ismail Basha and Saira khatheeja: association of hsCRP with diabetic and non-diabetic individuals. Jordan J Biol Sci 2010, 3(1):7-12.
12. Steven M. Haffner: the metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiology 2006, 97:3A-11A.
13. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379. 10.1053/jhep.2002.30692, 11826411.
14. Ikeda Y, Fujii J, Taniguchi N, Meister A. Expression of an active glycosylated human gamma-glutamyl transpeptidase mutant that lacks a membrane anchor domain. Proc Natl Acad Sci USA 1995, 92:126-130. 10.1073/pnas.92.1.126, 42830, 7816801.
15. Moussa SA. Oxidative stress in diabetes mellitus. Rom J Biophys 2008, 18(3):225-236.
16. Thorand B, Loewel H, Schneider A. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA augsburg cohort study, 1984-1998. Arch Intern Med 2003, 163:93-9.20. 10.1001/archinte.163.1.93, 12523922.
17. Targher G, Seidell JC, Tonoli M, Muggeo M, De Sandre G, Cigolini M. The white blood cell count: its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. J Intern Med 1996, 239:435-441. 10.1046/j.1365-2796.1996.815000.x, 8642236.
18. Facchini F, Hollenbeck CB, Chen YN, Chen YD, Reaven GM. Demonstration of a relationship between white blood cell count, insulin resistance, and several risk factors for coronary heart disease in women. J Intern Med 1992, 232:267-272. 10.1111/j.1365-2796.1992.tb00582.x, 1402624.
19. Sharma R, Sharma S, Kaushik GG. Gamma-glutamyltransferase (GGT) - a novel marker of endothelial dysfunction. JIACM 2010, 11(1):26-30.
20. Dilshad Ahmed K, Shazia Q. Evaluation of cardiac risk by oxidative stress and inflammatory markers in diabetic patients. Pak J Med Sci 2009, 25:5.
21. Sarinnapakorn V, Wanicagool W. Association between hs-CRP and Hba1c in overweight type 2 diabetic female patients. J Med Assoc Thai 2013, 96(3):S54-58.
22. Bahceci M, Tuzcu A, Ogun C, Canoruc N, Iltimur K, Aslan C. Is serum C-reactive protein concentration correlated with HbA1c and insulin resistance in Type 2 diabetic men with or without coronary heart disease. J Endocrinol Invest 2005, 28(2):145-150.
23. Thamer C, Tschritter O, Haap M, et al. Elevated serum GGT concentrations predict reduced insulin sensitivity and increased intra-hepatic lipids. Horm Metab Res 2005, 37:246-251. 10.1055/s-2005-861411, 15952086.
24. Andre P, Balkau B, Born C, Charles MA, Eschwege E. Three-year increase of gamma-glutamyltransferase level and development of type 2 diabetes in middle-aged men and women: the D.E.S.I.R. cohort. Diabetologia 2006, 49:2599-2603. 10.1007/s00125-006-0418-x, 1975686, 16969645.
25. Marchesini G, Avagnina S, Barantani EG, Ciccarone AM, Corica F, Dall'Aglio E, Dalle Grave R, Morpurgo PS, Tomasi F, Vitacolonna E. Aminotransferase and gamma-glutamyltranspeptidase levels in obesity are associated with insulin resistance and the metabolic syndrome. J Endocrinol Invest 2005, 28:333-339.
26. Lee DH, Silventoinen K, Jacobs DR, Jousilahti P, Tuomileto J. Gamma-glutamyltransferase, obesity, and the risk of type 2 diabetes: observational cohort study among 20,158 middle-aged men and women. J Clin Endocrinol Metab 2004, 89:5410-5414. 10.1210/jc.2004-0505, 15531490.
27. Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM 2003, 96:699-709. 10.1093/qjmed/hcg120, 14500857.
28. Targher G. Nonalcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007, 24:1-6.
29. Lee DH, Blomhoff R, Jacobs DR. Is serum gamma glutamyltransferase a marker of oxidative stress?. Free Radic Res 2004, 38:535-539. 10.1080/10715760410001694026, 15346644.
30. Paolicchi A, Emdin M, Ghliozeni E, et al. Images in cardiovascular medicine: human atherosclerotic plaques contain gamma-glutamyl transpeptidase enzyme activity. Circulation 2004, 109:1440. 10.1161/01.CIR.0000120558.41356.E6, 15037540.
31. Emdin M, Passino C, Pompella A, Paolicchi A. Gamma-glutamyltransferase as a cardiovascular risk factor. Eur Heart J 2006, 27:2145-2146. 10.1093/eurheartj/ehl151, 16835265.
32. Hanley AJ, Williams K, Festa A, et al. Liver markers and development of the metabolic syndrome. The insulin resistance atherosclerosis study. Diabetes 2005, 54:3140-3147. 10.2337/diabetes.54.11.3140, 16249437.
33. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111:1448-1454. 10.1161/01.CIR.0000158483.13093.9D, 15781756.
34. Lee DH, Jacobs DR, Gross M, Kiefe CI, Roseman J, Lewis CE, Steffes M. Gammaglutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Clin Chem 2003, 49:1358-1366. 10.1373/49.8.1358, 12881453.
35. Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care 2005, 28:1757-1762. 10.2337/diacare.28.7.1757, 15983331.
36. Targher G, Bertolini L, Poli F, et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54:3541-3546. 10.2337/diabetes.54.12.3541, 16306373.
37. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003, 27(3):S53-S55.
38. Hsueh WA, Quinones MJ. Role of endothelial dysfunction in insulin resistance. Am J Cardiol 2003, 92:10J-17J.
39. Van Oostrom AJ, Sijmonsma TP, Verseyden C, Jansen EH, de Koning EJ, Rabelink TJ, Castro Cabezas M. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. J Lipid Res 2003, 44:576-583. 10.1194/jlr.M200419-JLR200, 12562833.